Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis면역저하 집단에서 SARS-CoV-2 백신의 1차, 2차, 3차 접종 후 혈청전환: 체계적인 검토 및 메타분석Review Published on 2022-08-082022-09-12 Journal: Virology Journal [Category] SARS, 진단, [키워드] 95% CI administration Analysis article Autoimmune Autoimmune disease booster dose conditions conducted COVID-19 COVID-19 vaccine database develop dose dose administration Efficacy etiology evaluate first dose General population heterogeneity high-risk population higher risk Immunity Immunocompromised Immunocompromised patient investigated item less lowest malignancy material Meta-analysis mRNA mRNA vaccine observational study Patient patients Prevalence R software Reporting review rising SARS-CoV-2 SARS-CoV-2 vaccine searched second dose sensitivity analysis Seroconversion Severe COVID-19 Infection subgroup analysis systematic review the vaccine transplantation vaccination Vaccine was performed Web of Science [DOI] 10.1186/s12985-022-01858-3 PMC 바로가기 [Article Type] Review
Communicating about COVID-19 vaccine development and safetyRandomized Controlled Trial Published on 2022-08-052022-10-05 Journal: PLoS ONE [Category] 임상, [키워드] assigned belief Communicating conducted control group COVID-19 COVID-19 mRNA vaccines COVID-19 vaccine COVID-19 vaccine development driver experiment expressed Factor identify IMPROVE Intention Intervention MOST promote Randomly reduce refusal Research risk significantly tested the vaccine vaccination intentions Vaccine vaccine intentions veteran with COVID-19 [DOI] 10.1371/journal.pone.0272426 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans미국 참전용사를 대상으로 실시한 대조 테스트 음성 사례 대조 연구에서 오미크론 및 델타 변이체에 대한 mRNA COVID-19 백신의 효과Article Published on 2022-08-032022-09-11 Journal: BMJ Open [Category] SARS, 변종, [키워드] 95% CI Against Antigen booster booster dose booster doses booster vaccination case-control study Comorbidities conducted death Delta delta variant dose effective Effectiveness Electronic health record Epidemiology Health health administration health record hospitalisation immunology Infection male Messenger RNA mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA vaccines Older omicron outcome positive result public health SARS-CoV-2 PCR SARS-CoV-2 test SARS-CoV-2 variant severe disease Symptoms the vaccine vaccination vaccinee vaccinees variant variants veteran [DOI] 10.1136/bmjopen-2022-063935 PMC 바로가기 [Article Type] Article
Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccinationJanus kinase inhibitor로 치료받은 류마티스 관절염 환자, BNT162b2 백신 접종 후 체액성 면역 반응 감소Article Published on 2022-08-032022-09-12 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, [키워드] Activation alteration analysed anti-spike antibodies anti-Spike IgG Anti-spike IgG antibody antibodies antibody antibody titres Arthritis B cell B cell responses B cells B-lymphocytes BNT162b2 BNT162b2 vaccine collected COVID-19 COVID-19 vaccine determine dose Efficacy elicited ELISA expression germinal centre healthy individual healthy individuals humoral humoral immune response Humoral immunity IgA antibody individuals JAK inhibitor Janus kinase Janus kinase inhibitor Janus kinase inhibitors less mRNA-based COVID-19 vaccine neutralization activity Neutralization assay neutralization capacity Patient patients patients treated plasma plasma sample quantitative PCR reduced Rheumatoid rheumatoid arthritis SARS-CoV-2 SARS-COV-2 infection shown Spike protein suppressed the SARS-CoV-2 the vaccine titre treated vaccination Vaccine Vaccines Virus neutralization was reduced was used [DOI] 10.1093/rheumatology/keab879 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2새로운 인간 코로나바이러스 SARS-CoV, MERS-CoV 및 SARS-CoV-2에 대한 면역 반응 유도를 위한 3가 서브유닛 백신을 설계하기 위해 높은 처리량 및 포괄적인 면역정보학 접근법 적용Article Published on 2022-08-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 치료법, [키워드] acute respiratory syndrome added adjuvant against SARS-CoV Analysis Antigen antigens applied Applying approach B-cell binding affinity codon optimization complex conducted coronavirus disease Coronavirus disease 2019 CoV COVID-19 CoVs CTL defensin demonstrated disease docking epitope Epitopes facilitate HLA HTL HTLs human coronavirus IEDB IFN IFN-γ immune response immune responses immunogenic immunoinformatics In silico cloning increased expression kDa MDs membrane MERS MERS-CoV MERS‐CoV MHC I Middle East Middle East respiratory syndrome molecular dynamics Molecular dynamics simulation molecular weight molecule Multi-epitope vaccine non-allergenic non-structural protein nucleocapsid PADRE Pan predicted Protein responses SARS-CoV SARS-CoV-2 SARS‐CoV secondary selected epitope sequence sequences Severe acute respiratory syndrome stability stimulate Structure subunit Subunit vaccine syndrome T lymphocyte TAT the vaccine trivalent Vaccine was used β-defensin [DOI] 10.1080/07391102.2021.1876774 PMC 바로가기 [Article Type] Article
A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries국가별 SARS-CoV-2 및 그 변이체 오미크론에 대한 포괄적인 게놈 연구, 돌연변이 스크리닝, 계통 발생 및 통계 분석Article Published on 2022-08-012022-09-11 Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition Analysis anticipated approach assist average B.1.1.529 B.1.617.2 bioinformatics Brazil changes in Complete confidence conserved Corona coronavirus country COVID-19 Delta determined by domain domains Drug discovery Effect evaluate Evolution full-length genome Genes genetic diversity Genome genome sequence Genome sequences genomic genomic sequence help heterozygosity highest identify in viral in-silico information isolates Japan MSN Mutation mutation analysis offer omicron Omicron variant Omicron variants ORF1 ORF10 ORF1ab ORF7a Phylogenetic Phylogenetic tree Phylogeny polymorphism Population predict prevalent Protein provide resource SARS-CoV-2 selected sequence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shape Spike protein standard error statistical analysis strain the Spike the vaccine these viruses TRS unique Vaccine variant variants Variation variations viral genome viral genome sequence viruses was determined was used were used Wuhan-Hu-1 [DOI] 10.1016/j.jiph.2022.07.002 PMC 바로가기 [Article Type] Article
COVID-19 vaccine acceptance and its determinants: A cross-sectional study among the socioeconomically disadvantaged communities living in Delhi, IndiaResearch article Published on 2022-08-012022-10-05 Journal: Vaccine: X [Category] 신약개발, [키워드] acute respiratory syndrome analysed Behavioural research carried Clusters collected Community conducted Coronavirus-2 COVID-19 COVID-19 vaccine cross-sectional cross-sectional survey effort examined Factor group Health Health beliefs identify Immunity India Logistic regression Older age predictor PROTECT questionnaire Randomly Regression Result SARS-CoV-2 selected Self-efficacy severity severity of COVID-19 socio-demographic susceptibility the SARS-CoV-2 the vaccine Urban communities Vaccine Vaccine acceptance Vaccine hesitancy variables [DOI] 10.1016/j.jvacx.2022.100171 [Article Type] Research article
People’s perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sampleResearch article Published on 2022-08-012022-10-05 Journal: Vaccine [Category] 변종, [키워드] Affect asked contribute country Coverage COVID-19 COVID-19 public policy COVID-19 vaccination COVID-19 vaccination certificate early phase events Factor favor finding form Health Hospitalization Increases individual individuals Italian Italian population Italy Judgment and decision-making Medical expenses pandemic participant Perspective predicted Result Risk perception Support tested the vaccine vaccination Vaccine Vaccine hesitancy [DOI] 10.1016/j.vaccine.2022.08.016 [Article Type] Research article